NovoCure Limited (NVCR)
(Real Time Quote from BATS)
$17.91 USD
+0.01 (0.06%)
Updated Aug 19, 2024 03:44 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for NovoCure Limited falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 912 | 970 | 939 | 854 | 328 |
Receivables | 84 | 112 | 111 | 118 | 88 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 38 | 29 | 24 | 27 | 24 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 1,034 | 1,112 | 1,074 | 999 | 440 |
Net Property & Equipment | 63 | 45 | 36 | 23 | 17 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 14 | 11 | 12 | 11 | 5 |
Total Assets | 1,146 | 1,192 | 1,140 | 1,052 | 479 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 94 | 85 | 73 | 54 | 37 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 85 | 74 | 70 | 60 | 49 |
Total Current Liabilities | 179 | 159 | 143 | 114 | 86 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 3 | 6 | 12 | 8 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 569 | 566 | 562 | 430 | 149 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8 | 5 | 5 | 6 | 4 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 784 | 750 | 729 | 575 | 262 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,353 | 1,222 | 1,100 | 1,111 | 871 |
Retained Earnings | -986 | -778 | -686 | -631 | -651 |
Other Equity | -5 | -2 | -3 | -4 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 363 | 441 | 410 | 477 | 218 |
Total Liabilities & Shareholder's Equity | 1,146 | 1,192 | 1,140 | 1,052 | 479 |
Total Common Equity | 363 | 441 | 410 | 477 | 218 |
Shares Outstanding | 106.80 | 104.90 | 103.80 | 101.80 | 98.90 |
Book Value Per Share | 3.39 | 4.21 | 3.95 | 4.68 | 2.20 |
Fiscal Year End for NovoCure Limited falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 955 | 874 | 912 | 923 | 941 |
Receivables | 98 | 87 | 84 | 88 | 91 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 40 | 42 | 38 | 37 | 33 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 1,093 | 1,003 | 1,034 | 1,048 | 1,065 |
Net Property & Equipment | 78 | 71 | 63 | 57 | 53 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 12 | 15 | 14 | 12 | 15 |
Total Assets | 1,212 | 1,121 | 1,146 | 1,146 | 1,159 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 90 | 84 | 94 | 80 | 83 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 79 | 76 | 85 | 77 | 68 |
Total Current Liabilities | 169 | 160 | 179 | 157 | 150 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 653 | 570 | 569 | 568 | 567 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 8 | 5 | 5 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 850 | 762 | 784 | 753 | 743 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,423 | 1,388 | 1,353 | 1,334 | 1,307 |
Retained Earnings | -1,058 | -1,024 | -986 | -938 | -889 |
Other Equity | -4 | -4 | -5 | -2 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 362 | 359 | 363 | 394 | 416 |
Total Liabilities & Shareholder's Equity | 1,212 | 1,121 | 1,146 | 1,146 | 1,159 |
Total Common Equity | 362 | 359 | 363 | 394 | 416 |
Shares Outstanding | 108.20 | 107.60 | 106.80 | 106.80 | 106.60 |
Book Value Per Share | 3.34 | 3.34 | 3.39 | 3.69 | 3.90 |